Where can I find news about PFS?

The latest headlines, third-party analysis, and SEC filings for Provident Financial Services, Inc. (PFS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are PFS's SEC filings?

Provident Financial Services, Inc. (PFS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are PFS's earnings call transcripts?

Full earnings call transcripts for Provident Financial Services, Inc. (PFS), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

PFS

Provident Financial Services, Inc.

NYSE·Banks, Regional · Financial Services

$23.22$0.02−0.09%

After hours·$23.22+0.00%

Market cap$3.03B·Market closed·Oct 26 4:00 PM EDT

News & Analysis

Provident Financial Services Can Still Move Up From Here
Provident Financial Services, Inc. remains a Buy due to robust asset quality, attractive valuation, and ongoing earnings growth. PFS's deposit base has grown, with high-cost brokered deposits at only 6.5% and uninsured deposits below the 30% risk threshold. Net interest margin improved to 3.48%, while forward P/E of 9.2 and trading near book value underscore the stock's undervaluation.
seekingalpha.comOct 26, 2026 · 4:21 PM
Why Provident Financial (PFS) is Poised to Beat Earnings Estimates Again
Provident Financial (PFS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.comOct 26, 2026 · 1:11 PM
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
gurufocus.comOct 25, 2026 · 12:00 PM
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
gurufocus.comOct 25, 2026 · 12:00 PM
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Positive results from the SAFFRON Phase III trial showed TAGRISSOÂ (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meani
gurufocus.comOct 25, 2026 · 12:00 PM
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod
gurufocus.comOct 25, 2026 · 5:00 AM
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR Newswire
gurufocus.comOct 25, 2026 · 4:00 AM
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.comOct 24, 2026 · 11:00 AM

SEC Filings

8-K
Aug 24, 2026View on SEC
424B5
Aug 24, 2026View on SEC
FWP
Aug 20, 2026View on SEC
FWP
Aug 20, 2026View on SEC
424B5
Aug 20, 2026View on SEC
8-K
Aug 14, 2026View on SEC

Frequently Asked Questions About PFS

Where can I find news about PFS?: The latest headlines, third-party analysis, and SEC filings for Provident Financial Services, Inc. (PFS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are PFS's SEC filings?: Provident Financial Services, Inc. (PFS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are PFS's earnings call transcripts?: Full earnings call transcripts for Provident Financial Services, Inc. (PFS), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

Provident Financial Services, Inc.

Frequently Asked Questions About PFS

Provident Financial Services, Inc.

Provident Financial Services Can Still Move Up From Here

Why Provident Financial (PFS) is Poised to Beat Earnings Estimates Again

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Frequently Asked Questions About PFS

Provident Financial Services Can Still Move Up From Here

Why Provident Financial (PFS) is Poised to Beat Earnings Estimates Again

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial